Carnosine vs Klotho
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Carnosine
Naturally occurring dipeptide (β-alanine + L-histidine) found at high concentrations in skeletal muscle and brain. Functions as a pH buffer, anti-glycation agent, antioxidant, and metal chelator. Extensively studied for athletic performance (pH buffering), neuroprotection, anti-aging (AGE formation prevention), and cataract research (eye drops).
Full profileKlotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profile| Carnosine | Klotho | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | β-alanyl-L-histidine, L-carnosine, brain dipeptide, muscle dipeptide | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain |
| Evidence | Research-stage | Research-stage |
| Dosing range | 500mg–2000mg mg, twice daily oral | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) |
| Administration | Oral (capsule/powder), Topical (eye drops — cataract research) | Intravenous (research), Subcutaneous injection |
| Key side effects | Generally well-tolerated, Mild GI discomfort at high doses (>2g/day), Rare: carnosinemia in carnosinase deficiency (genetic condition), Zinc chelation may reduce zinc availability at very high doses | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Carnosine — Oral (capsule/powder), Topical (eye drops — cataract research); Klotho — Intravenous (research), Subcutaneous injection.
- Dosing units differ: Carnosine is dosed in mg, Klotho in mcg/kg — they operate at different scales.
- Frequency: Carnosine is typically twice daily oral; Klotho is every 3–7 days IV or SC (research).
How each works
Carnosine
Carnosine's multi-mechanism activity explains interest across several research domains. Its histidine moiety buffers intramuscular pH during high-intensity exercise, directly improving performance. As an anti-glycation agent, carnosine quenches reactive carbonyl species that form advanced glycation end-products (AGEs), potentially slowing protein crosslinking associated with tissue aging. Brain carnosine concentrations correlate with cognitive vitality in aging research.
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.